We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Early Urine Collection Improves Assay for HIV-TB

By LabMedica International staff writers
Posted on 25 May 2017
There is an urgent need for new, accurate, and rapid non-sputum-based tuberculosis (TB) diagnostics that have high sensitivity in patients with human immunodeficiency virus (HIV/TB) co-infection with advanced immunosuppression.

Early morning urine (EMU) is accepted as a useful method for improving the concentrations of a number of antigens and analytes found in human urine. More...
The strategy has been shown to improve the yield of urine culture for TB diagnosis.

Scientists at the University of Cape Town prospectively recruited HIV-infected adults, all over the age of 18 years, between June 2012 and February 2014 from four hospitals in South Africa. The reference standard for TB was single sputum sample positive liquid TB culture and/or Xpert MTB/RIF assay. Paired samples of EMU and random urine were collected from each patient.

The lateral flow lipoarabinomannan assay (LF-LAM) was done on random urine samples at the bedside and additionally on matched fresh bedside EMU samples the following day. All samples were tested using the Alere Determine-TB LAM Ag lateral flow assay. LF-LAM was graded using the pre-January 2014, with grade 1 and 2 manufacturer-designated cut-off-points (the latter designated grade 1 after January 2014).

There were 123 HIV-infected patients who had commenced anti-TB treatment and provided matched random and EMU samples. There were 33% (41/123) who had definite TB and 67% (82/123) had probable TB. Amongst those with definite TB LF-LAM sensitivity using the grade 2 cut-off-point, increased from 12% (5/43) to 39% (16/41) with random versus EMU, respectively. Similarly, amongst probable TB, LF-LAM sensitivity increased from 10% (8/83) to 24% (20/82). LF-LAM specificity was not determined.

The authors concluded that the study highlights the diagnostic implications of the timing of sample collection with EMU testing significantly improving LF-LAM sensitivity in hospitalized TB/HIV co-infected patients. Factors known to affect LAM concentration, such as CD4 cell count, age and culture/Xpert MTB/RIF status were not associated with an increased LF-LAM grade. The data presented have implications for clinical practice. The study was published on May 12, 2017, in the journal BMC Infectious Diseases.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.